ArticlemedRxiv : the preprint server for health sciences2025
Personalization of Radiotherapy Dose in HPV Positive Oropharynx Cancer Using GARD.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 4 countries.
Funding
Abstract
A central clinical goal for patients with HPV-positive oropharynx cancer has been to reduce radiation doses while maintaining cure rates. Recent results of Phase 3 prospective trial HN005 demonstrated that RT dose de-escalation can not be safely done based on clinical factors alone. We have previously shown that the genomic adjusted radiation dose (GARD) is predictive of radiation treatment benefit and can be used to guide RT dose selection. We hypothesize that GARD can be used to guide RT dose de-escalation in HPV-positive OPSCC patients. Gene expression was analyzed for 191 formalin-fixed paraffin-embedded samples from HPV-positive OPSCC patients within an international, multi-institutional, prospective/retrospective observational study including patients with AJCC 8th edition stage I-III. Two RT dose fractionations were utilized for the majority of primary RT cases (70 Gy in 35 fractions or 69.96 Gy in 33 fractions). Median RT dose was 70 Gy (range 51.0-74.0), survival at 36 months and 60 months was 94.1% and 87.3%, respectively. Cox proportional hazards analyses were performed with GARD as a continuous variable and time-dependent ROC analyses compared the performance of GARD to clinical variables alone. Despite near-uniform RT dosing, GARD reveals significant heterogeneity (range 15.4 - 71.7) in predicted effect. In univariate analysis, GARD was associated with an improvement in OS (HR = 0.941 (0.888, 0.998), p = 0.041). In multivariable analysis, each unit increase in GARD was associated with an improvement in OS (HR = 0.943 (0.891, 0.999), p = 0.046) where stage was not (T stage HR = 1.992 (0.711-5.576), p=0.190, N stage HR = 2.367 (0.867-6.460), p=0.093). ROC analysis for GARD at 36 months yielded an AUC of 78.26 (65.14, 91.38) compared with 71.20 (54.47, 87.93) for standard clinical variables. We identify two GARD-based strategies to RT dose personalization which are predicted to yield improved clinical outcomes, while delivering an average lower RT dose. In this multi-institutional cohort of patients with HPV-positive OPSCC, GARD associates with OS, outperforms standard clinical variables and provides a novel genomic strategy to RT dose personalization. We propose that GARD should be incorporated in the diagnostic workup of HPV-positive OPSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.